메뉴 건너뛰기




Volumn 31, Issue 1, 2013, Pages 213-229

Investigational agents in development for the treatment of ovarian cancer

Author keywords

Angiogenesis; Ovarian cancer; Personalized therapy; Resistance; Targeted therapy

Indexed keywords

4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AFLIBERCEPT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BMN 673; CABOZANTINIB; CEDIRANIB; DASATINIB; ERLOTINIB; EVEROLIMUS; FARLETUZUMAB; GANITUMAB; INIPARIB; MM 121; NINTEDANIB; NIRAPARIB; OLAPARIB; PAZOPANIB; PERIFOSINE; RUCAPARIB; SARACATINIB; SELUMETINIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VELIPARIB; XL 147;

EID: 84873095075     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9837-3     Document Type: Review
Times cited : (25)

References (170)
  • 1
    • 0003964363 scopus 로고    scopus 로고
    • American Cancer Society American Cancer Society Atlanta
    • American Cancer Society (2012) Cancer facts & figures, 2012. American Cancer Society, Atlanta
    • (2012) Cancer Facts & Figures, 2012
  • 2
    • 77950188167 scopus 로고    scopus 로고
    • Achievements and unmet needs in the management of advanced ovarian cancer
    • 20056266 1:CAS:528:DC%2BC3cXktlCjtbg%3D
    • Guarneri V, Piacentini F, Barbieri E, Conte PF (2010) Achievements and unmet needs in the management of advanced ovarian cancer. Gynecol Oncol 117:152-158
    • (2010) Gynecol Oncol , vol.117 , pp. 152-158
    • Guarneri, V.1    Piacentini, F.2    Barbieri, E.3    Conte, P.F.4
  • 5
    • 70349878651 scopus 로고    scopus 로고
    • Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: A phase 3, open-label, randomised controlled trial
    • 19767092 1:CAS:528:DC%2BD1MXht1Ogu7fJ
    • Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374:1331-1338
    • (2009) Lancet , vol.374 , pp. 1331-1338
    • Katsumata, N.1    Yasuda, M.2    Takahashi, F.3    Isonishi, S.4    Jobo, T.5    Aoki, D.6    Tsuda, H.7    Sugiyama, T.8    Kodama, S.9    Kimura, E.10    Ochiai, K.11    Noda, K.12
  • 6
    • 37549072095 scopus 로고    scopus 로고
    • National Comprehensive Cancer Network Including Fallopian Tube Cancer and Primary Peritoneal Cancer. V.2.2012 Accessed 8 February 2012
    • National Comprehensive Cancer Network (2012) NCCN Clinical Practice Guidelines in Oncology™. Ovarian Cancer. Including Fallopian Tube Cancer and Primary Peritoneal Cancer. V.2.2012. http://www.nccn.org/professionals/ physician-gls/PDF/ovarian.pdf. Accessed 8 February 2012
    • (2012) NCCN Clinical Practice Guidelines in Oncology™. Ovarian Cancer
  • 9
    • 4444324696 scopus 로고    scopus 로고
    • VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma
    • 15350351 1:CAS:528:DC%2BD2cXntlOht7c%3D
    • Chen H, Ye D, Xie X, Chen B, Lu W (2004) VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecol Oncol 94:630-635
    • (2004) Gynecol Oncol , vol.94 , pp. 630-635
    • Chen, H.1    Ye, D.2    Xie, X.3    Chen, B.4    Lu, W.5
  • 10
    • 77950690217 scopus 로고    scopus 로고
    • Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer
    • 20229258
    • Delli Carpini J, Karam AK, Montgomery L (2010) Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis 13:43-58
    • (2010) Angiogenesis , vol.13 , pp. 43-58
    • Delli Carpini, J.1    Karam, A.K.2    Montgomery, L.3
  • 12
    • 0033050656 scopus 로고    scopus 로고
    • Markedly elevated levels of vascular endothelial growth factor in malignant ascites
    • 10379858 1:STN:280:DyaK1Mzgs1GhtA%3D%3D
    • Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM (1999) Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 6:373-378
    • (1999) Ann Surg Oncol , vol.6 , pp. 373-378
    • Zebrowski, B.K.1    Liu, W.2    Ramirez, K.3    Akagi, Y.4    Mills, G.B.5    Ellis, L.M.6
  • 13
    • 36849083963 scopus 로고    scopus 로고
    • Bevacizumab for the treatment of epithelial ovarian cancer: Will this be its finest hour?
    • 18024860 1:CAS:528:DC%2BD2sXhsVKnsb%2FJ
    • Kaye SB (2007) Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour? J Clin Oncol 25:5150-5152
    • (2007) J Clin Oncol , vol.25 , pp. 5150-5152
    • Kaye, S.B.1
  • 14
    • 58149214155 scopus 로고    scopus 로고
    • Antiangiogenic drugs in ovarian cancer
    • 19002176 1:CAS:528:DC%2BD1MXjt1SgsQ%3D%3D
    • Kumaran GC, Jayson GC, Clamp AR (2009) Antiangiogenic drugs in ovarian cancer. Br J Cancer 100:1-7
    • (2009) Br J Cancer , vol.100 , pp. 1-7
    • Kumaran, G.C.1    Jayson, G.C.2    Clamp, A.R.3
  • 16
    • 36849019301 scopus 로고    scopus 로고
    • Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study
    • 18024863 1:CAS:528:DC%2BD2sXhsVKnsb%2FE
    • Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI (2007) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25:5165-5171
    • (2007) J Clin Oncol , vol.25 , pp. 5165-5171
    • Burger, R.A.1    Sill, M.W.2    Monk, B.J.3    Greer, B.E.4    Sorosky, J.I.5
  • 18
    • 84862339546 scopus 로고    scopus 로고
    • Pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancers: Results of a phase II study
    • Abstract 5061
    • del Carmen MG, Micha JP, Small LA, Street DG, Londhe A, McGowan T (2011) Pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancers: Results of a phase II study. J Clin Oncol 29: Abstract 5061
    • (2011) J Clin Oncol , vol.29
    • Del Carmen, M.G.1    Micha, J.P.2    Small, L.A.3    Street, D.G.4    Londhe, A.5    McGowan, T.6
  • 19
    • 84861736119 scopus 로고    scopus 로고
    • OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
    • Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol
    • (2012) J Clin Oncol
    • Aghajanian, C.1    Blank, S.V.2    Goff, B.A.3    Judson, P.L.4    Teneriello, M.G.5    Husain, A.6    Sovak, M.A.7    Yi, J.8    Nycum, L.R.9
  • 21
    • 80051549914 scopus 로고    scopus 로고
    • Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: Results of a Phase 2 Study
    • 21815133 1:CAS:528:DC%2BC3MXps12gu7Y%3D
    • McGonigle KF, Muntz HG, Vuky J, Paley PJ, Veljovich DS, Greer BE, Goff BA, Gray HJ, Malpass TW (2011) Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a Phase 2 Study. Cancer 117:3731-3740
    • (2011) Cancer , vol.117 , pp. 3731-3740
    • McGonigle, K.F.1    Muntz, H.G.2    Vuky, J.3    Paley, P.J.4    Veljovich, D.S.5    Greer, B.E.6    Goff, B.A.7    Gray, H.J.8    Malpass, T.W.9
  • 22
    • 79960473821 scopus 로고    scopus 로고
    • Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers
    • 21601912 1:CAS:528:DC%2BC3MXovFOht7Y%3D
    • Kudoh K, Takano M, Kouta H, Kikuchi R, Kita T, Miyamoto M, Watanabe A, Kato M, Goto T, Kikuchi Y (2011) Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers. Gynecol Oncol 122:233-237
    • (2011) Gynecol Oncol , vol.122 , pp. 233-237
    • Kudoh, K.1    Takano, M.2    Kouta, H.3    Kikuchi, R.4    Kita, T.5    Miyamoto, M.6    Watanabe, A.7    Kato, M.8    Goto, T.9    Kikuchi, Y.10
  • 23
    • 79952680888 scopus 로고    scopus 로고
    • A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma
    • Abstract 5009
    • Tillmanns TD, Lowe MP, Schwartzberg LS, Walker MS, Stepanski EJ (2010) A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. J Clin Oncol 28: Abstract 5009
    • (2010) J Clin Oncol , vol.28
    • Tillmanns, T.D.1    Lowe, M.P.2    Schwartzberg, L.S.3    Walker, M.S.4    Stepanski, E.J.5
  • 25
    • 45549099056 scopus 로고    scopus 로고
    • Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II Consortia
    • 18423560 1:CAS:528:DC%2BD1cXnvVOlu7s%3D
    • Nimeiri HS, Oza AM, Morgan RJ, Friberg G, Kasza K, Faoro L, Salgia R, Stadler WM, Vokes EE, Fleming GF (2008) Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 110:49-55
    • (2008) Gynecol Oncol , vol.110 , pp. 49-55
    • Nimeiri, H.S.1    Oza, A.M.2    Morgan, R.J.3    Friberg, G.4    Kasza, K.5    Faoro, L.6    Salgia, R.7    Stadler, W.M.8    Vokes, E.E.9    Fleming, G.F.10
  • 26
    • 34447298651 scopus 로고    scopus 로고
    • A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer
    • 17343605 1:STN:280:DC%2BD2svhsFGktQ%3D%3D
    • Micha JP, Goldstein BH, Rettenmaier MA, Genesen M, Graham C, Bader K, Lopez KL, Nickle M, Brown JV III (2007) A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer 17:771-776
    • (2007) Int J Gynecol Cancer , vol.17 , pp. 771-776
    • Micha, J.P.1    Goldstein, B.H.2    Rettenmaier, M.A.3    Genesen, M.4    Graham, C.5    Bader, K.6    Lopez, K.L.7    Nickle, M.8    Brown Iii, J.V.9
  • 30
    • 78650450402 scopus 로고    scopus 로고
    • ICON7: A phase III randomised gynaecologic cancer intergroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC)
    • on behalf of GCIG ICON7 collaborators Abstract LBA4
    • Perren T, Swart AM, Pfisterer J, Ledermann J, Lortholary A, Kristensen G, Carey M, Beale P, Cervantes A, Oza A, on behalf of GCIG ICON7 collaborators (2010) ICON7: a phase III randomised gynaecologic cancer intergroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC). Ann Oncol 21:viii2-3, Abstract LBA4
    • (2010) Ann Oncol , vol.21 , pp. 2-3
    • Perren, T.1    Swart, A.M.2    Pfisterer, J.3    Ledermann, J.4    Lortholary, A.5    Kristensen, G.6    Carey, M.7    Beale, P.8    Cervantes, A.9    Oza, A.10
  • 32
    • 84856509199 scopus 로고    scopus 로고
    • Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: A phase 2, randomised, double-blind, placebo-controlled study
    • 22192729 1:CAS:528:DC%2BC38XitVSmu74%3D
    • Gotlieb WH, Amant F, Advani S, Goswami C, Hirte H, Provencher D, Somani N, Yamada SD, Tamby JF, Vergote I (2012) Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 13:154-162
    • (2012) Lancet Oncol , vol.13 , pp. 154-162
    • Gotlieb, W.H.1    Amant, F.2    Advani, S.3    Goswami, C.4    Hirte, H.5    Provencher, D.6    Somani, N.7    Yamada, S.D.8    Tamby, J.F.9    Vergote, I.10
  • 33
    • 36849005801 scopus 로고    scopus 로고
    • VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study
    • Abstract 5508
    • Tew WP, Colombo N, Ray-Coquard I, Oza A, del Campo J, Scambia G, Spriggs D (2007) VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): preliminary results of a randomized, multicenter phase II study. J Clin Oncol 25: Abstract 5508
    • (2007) J Clin Oncol , vol.25
    • Tew, W.P.1    Colombo, N.2    Ray-Coquard, I.3    Oza, A.4    Del Campo, J.5    Scambia, G.6    Spriggs, D.7
  • 35
    • 67349129399 scopus 로고    scopus 로고
    • Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies
    • 19394890 1:CAS:528:DC%2BD1MXnt1ehsr0%3D
    • Rapisarda A, Melillo G (2009) Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resist Updat 12:74-80
    • (2009) Drug Resist Updat , vol.12 , pp. 74-80
    • Rapisarda, A.1    Melillo, G.2
  • 36
    • 47949099628 scopus 로고    scopus 로고
    • Modes of resistance to anti-angiogenic therapy
    • 18650835 1:CAS:528:DC%2BD1cXovV2lsrk%3D
    • Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592-603
    • (2008) Nat Rev Cancer , vol.8 , pp. 592-603
    • Bergers, G.1    Hanahan, D.2
  • 37
    • 77951692165 scopus 로고    scopus 로고
    • Molecular mechanisms of resistance to tumour anti-angiogenic strategies
    • 20224655
    • Grepin R, Pages G (2010) Molecular mechanisms of resistance to tumour anti-angiogenic strategies. J Oncol 2010:835680
    • (2010) J Oncol , vol.2010 , pp. 835680
    • Grepin, R.1    Pages, G.2
  • 38
    • 0027365546 scopus 로고
    • Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms
    • 8402626 1:CAS:528:DyaK2cXivVequw%3D%3D
    • Henriksen R, Funa K, Wilander E, Backstrom T, Ridderheim M, Oberg K (1993) Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms. Cancer Res 53:4550-4554
    • (1993) Cancer Res , vol.53 , pp. 4550-4554
    • Henriksen, R.1    Funa, K.2    Wilander, E.3    Backstrom, T.4    Ridderheim, M.5    Oberg, K.6
  • 39
    • 1842582507 scopus 로고    scopus 로고
    • Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines
    • 15047217 1:CAS:528:DC%2BD2cXisFyltbg%3D
    • Apte SM, Bucana CD, Killion JJ, Gershenson DM, Fidler IJ (2004) Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. Gynecol Oncol 93:78-86
    • (2004) Gynecol Oncol , vol.93 , pp. 78-86
    • Apte, S.M.1    Bucana, C.D.2    Killion, J.J.3    Gershenson, D.M.4    Fidler, I.J.5
  • 40
    • 0031785456 scopus 로고    scopus 로고
    • The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium
    • 9784315 1:CAS:528:DyaK1cXnsVWqsLc%3D
    • Dabrow MB, Francesco MR, McBrearty FX, Caradonna S (1998) The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium. Gynecol Oncol 71:29-37
    • (1998) Gynecol Oncol , vol.71 , pp. 29-37
    • Dabrow, M.B.1    Francesco, M.R.2    McBrearty, F.X.3    Caradonna, S.4
  • 42
    • 33645506349 scopus 로고    scopus 로고
    • Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer
    • 16331269 1:CAS:528:DC%2BD28XivFOmt7g%3D
    • Matei D, Emerson RE, Lai YC, Baldridge LA, Rao J, Yiannoutsos C, Donner DD (2006) Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer. Oncogene 25:2060-2069
    • (2006) Oncogene , vol.25 , pp. 2060-2069
    • Matei, D.1    Emerson, R.E.2    Lai, Y.C.3    Baldridge, L.A.4    Rao, J.5    Yiannoutsos, C.6    Donner, D.D.7
  • 43
    • 15544384846 scopus 로고    scopus 로고
    • Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers
    • 15791568 1:CAS:528:DC%2BD2MXis1Grsbg%3D
    • Wilczynski SP, Chen YY, Chen W, Howell SB, Shively JE, Alberts DS (2005) Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers. Hum Pathol 36:242-249
    • (2005) Hum Pathol , vol.36 , pp. 242-249
    • Wilczynski, S.P.1    Chen, Y.Y.2    Chen, W.3    Howell, S.B.4    Shively, J.E.5    Alberts, D.S.6
  • 46
    • 0027142057 scopus 로고
    • Basic fibroblast growth factor and its receptor messenger ribonucleic acids are expressed in human ovarian epithelial neoplasms
    • 8267056
    • Di Blasio AM, Cremonesi L, Vigano P, Ferrari M, Gospodarowicz D, Vignali M, Jaffe RB (1993) Basic fibroblast growth factor and its receptor messenger ribonucleic acids are expressed in human ovarian epithelial neoplasms. Am J Obstet Gynecol 169:1517-1523
    • (1993) Am J Obstet Gynecol , vol.169 , pp. 1517-1523
    • Di Blasio, A.M.1    Cremonesi, L.2    Vigano, P.3    Ferrari, M.4    Gospodarowicz, D.5    Vignali, M.6    Jaffe, R.B.7
  • 47
    • 0030866653 scopus 로고    scopus 로고
    • Expression of basic fibroblast growth factor and its mRNA in advanced ovarian cancers
    • 9378151 1:STN:280:DyaK1c%2FhvVarsg%3D%3D
    • Fujimoto J, Ichigo S, Hori M, Hirose R, Sakaguchi H, Tamaya T (1997) Expression of basic fibroblast growth factor and its mRNA in advanced ovarian cancers. Eur J Gynaecol Oncol 18:349-352
    • (1997) Eur J Gynaecol Oncol , vol.18 , pp. 349-352
    • Fujimoto, J.1    Ichigo, S.2    Hori, M.3    Hirose, R.4    Sakaguchi, H.5    Tamaya, T.6
  • 48
    • 0035855624 scopus 로고    scopus 로고
    • Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer
    • 11593393 1:CAS:528:DC%2BD3MXntlSgt70%3D
    • Steele IA, Edmondson RJ, Bulmer JN, Bolger BS, Leung HY, Davies BR (2001) Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer. Oncogene 20:5878-5887
    • (2001) Oncogene , vol.20 , pp. 5878-5887
    • Steele, I.A.1    Edmondson, R.J.2    Bulmer, J.N.3    Bolger, B.S.4    Leung, H.Y.5    Davies, B.R.6
  • 51
    • 0031834239 scopus 로고    scopus 로고
    • A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF
    • 9521897 1:CAS:528:DyaK1cXjslemsLg%3D
    • Benjamin LE, Hemo I, Keshet E (1998) A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125:1591-1598
    • (1998) Development , vol.125 , pp. 1591-1598
    • Benjamin, L.E.1    Hemo, I.2    Keshet, E.3
  • 52
    • 1442290142 scopus 로고    scopus 로고
    • Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms
    • 14657001 1:CAS:528:DC%2BD2cXht1Gjtrg%3D
    • Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, Menger MD, Ullrich A, Vajkoczy P (2004) Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 18:338-340
    • (2004) FASEB J , vol.18 , pp. 338-340
    • Erber, R.1    Thurnher, A.2    Katsen, A.D.3    Groth, G.4    Kerger, H.5    Hammes, H.P.6    Menger, M.D.7    Ullrich, A.8    Vajkoczy, P.9
  • 53
    • 26644471951 scopus 로고    scopus 로고
    • Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
    • 16226705 1:CAS:528:DC%2BD2MXhtFOrtLrF
    • Casanovas O, Hicklin DJ, Bergers G, Hanahan D (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8:299-309
    • (2005) Cancer Cell , vol.8 , pp. 299-309
    • Casanovas, O.1    Hicklin, D.J.2    Bergers, G.3    Hanahan, D.4
  • 55
    • 0038476608 scopus 로고    scopus 로고
    • Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
    • 12727920 1:CAS:528:DC%2BD3sXjsFCrsr4%3D
    • Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287-1295
    • (2003) J Clin Invest , vol.111 , pp. 1287-1295
    • Bergers, G.1    Song, S.2    Meyer-Morse, N.3    Bergsland, E.4    Hanahan, D.5
  • 57
    • 29144484059 scopus 로고    scopus 로고
    • Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions
    • 16172144 1:CAS:528:DC%2BD2MXht1OqtL7P
    • Laschke MW, Elitzsch A, Vollmar B, Vajkoczy P, Menger MD (2006) Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions. Hum Reprod 21:262-268
    • (2006) Hum Reprod , vol.21 , pp. 262-268
    • Laschke, M.W.1    Elitzsch, A.2    Vollmar, B.3    Vajkoczy, P.4    Menger, M.D.5
  • 60
    • 58149219264 scopus 로고    scopus 로고
    • A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial
    • Abstract 5521
    • Hirte HW, Vidal L, Fleming GF, Sugimoto AK, Morgan RJ, Biagi JJ, Wang L, McGill S, Ivy SP, Oza AM (2008) A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: final results of a PMH, Chicago and California consortia trial. J Clin Oncol 26: Abstract 5521
    • (2008) J Clin Oncol , vol.26
    • Hirte, H.W.1    Vidal, L.2    Fleming, G.F.3    Sugimoto, A.K.4    Morgan, R.J.5    Biagi, J.J.6    Wang, L.7    McGill, S.8    Ivy, S.P.9    Oza, A.M.10
  • 61
    • 80053232638 scopus 로고    scopus 로고
    • Initial toxicity assessment of ICON6: A randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer
    • Raja FA, Griffin CL, Qian W, Hirte H, Parmar MK, Swart AM, Ledermann JA (2011) Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer. Br J Cancer
    • (2011) Br J Cancer
    • Raja, F.A.1    Griffin, C.L.2    Qian, W.3    Hirte, H.4    Parmar, M.K.5    Swart, A.M.6    Ledermann, J.A.7
  • 63
    • 77951895481 scopus 로고    scopus 로고
    • A phase i open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
    • 19889612
    • du Bois A, Huober J, Stopfer P, Pfisterer J, Wimberger P, Loibl S, Reichardt VL, Harter P (2010) A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. Ann Oncol 21:370-375
    • (2010) Ann Oncol , vol.21 , pp. 370-375
    • Du Bois, A.1    Huober, J.2    Stopfer, P.3    Pfisterer, J.4    Wimberger, P.5    Loibl, S.6    Reichardt, V.L.7    Harter, P.8
  • 65
    • 57349179851 scopus 로고    scopus 로고
    • Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy
    • 19037839 1:CAS:528:DC%2BD1MXmvFKmtg%3D%3D
    • Sloan B, Scheinfeld NS (2008) Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr Opin Investig Drugs 9:1324-1335
    • (2008) Curr Opin Investig Drugs , vol.9 , pp. 1324-1335
    • Sloan, B.1    Scheinfeld, N.S.2
  • 72
    • 81155148279 scopus 로고    scopus 로고
    • Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group
    • 21955480 1:CAS:528:DC%2BC3MXhsVOisrzM
    • Ramasubbaiah R, Perkins SM, Schilder J, Whalen C, Johnson CS, Callahan M, Jones T, Sutton G, Matei D (2011) Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group. Gynecol Oncol 123:499-504
    • (2011) Gynecol Oncol , vol.123 , pp. 499-504
    • Ramasubbaiah, R.1    Perkins, S.M.2    Schilder, J.3    Whalen, C.4    Johnson, C.S.5    Callahan, M.6    Jones, T.7    Sutton, G.8    Matei, D.9
  • 73
    • 77956799700 scopus 로고    scopus 로고
    • Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: A study of the Princess Margaret Hospital Phase II Consortium
    • 20847613
    • Welch SA, Hirte HW, Elit L, Schilder RJ, Wang L, Macalpine K, Wright JJ, Oza AM (2010) Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium. Int J Gynecol Cancer 20:787-793
    • (2010) Int J Gynecol Cancer , vol.20 , pp. 787-793
    • Welch, S.A.1    Hirte, H.W.2    Elit, L.3    Schilder, R.J.4    Wang, L.5    MacAlpine, K.6    Wright, J.J.7    Oza, A.M.8
  • 74
    • 0037468875 scopus 로고    scopus 로고
    • Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase
    • 12646019 1:CAS:528:DC%2BD3sXhslSlsbg%3D
    • Sun L, Liang C, Shirazian S, Zhou Y, Miller T, Cui J, Fukuda JY, Chu JY, Nematalla A, Wang X, Chen H, Sistla A, Luu TC, Tang F, Wei J, Tang C (2003) Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 46:1116-1119
    • (2003) J Med Chem , vol.46 , pp. 1116-1119
    • Sun, L.1    Liang, C.2    Shirazian, S.3    Zhou, Y.4    Miller, T.5    Cui, J.6    Fukuda, J.Y.7    Chu, J.Y.8    Nematalla, A.9    Wang, X.10    Chen, H.11    Sistla, A.12    Luu, T.C.13    Tang, F.14    Wei, J.15    Tang, C.16
  • 75
    • 78650874372 scopus 로고    scopus 로고
    • SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer
    • 12748309 1:CAS:528:DC%2BD3sXkvVersbw%3D
    • Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471-478
    • (2003) Mol Cancer Ther , vol.2 , pp. 471-478
    • Abrams, T.J.1    Lee, L.B.2    Murray, L.J.3    Pryer, N.K.4    Cherrington, J.M.5
  • 80
    • 79251585977 scopus 로고    scopus 로고
    • A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: An NCIC Clinical Trials Group Study
    • 20705911 1:STN:280:DC%2BC3M7ltFWltQ%3D%3D
    • Biagi JJ, Oza AM, Chalchal HI, Grimshaw R, Ellard SL, Lee U, Hirte H, Sederias J, Ivy SP, Eisenhauer EA (2011) A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann Oncol 22:335-340
    • (2011) Ann Oncol , vol.22 , pp. 335-340
    • Biagi, J.J.1    Oza, A.M.2    Chalchal, H.I.3    Grimshaw, R.4    Ellard, S.L.5    Lee, U.6    Hirte, H.7    Sederias, J.8    Ivy, S.P.9    Eisenhauer, E.A.10
  • 81
    • 81155131273 scopus 로고    scopus 로고
    • A phase II trial of sunitinib in recurrent and refractory ovarian, fallopian tube, and peritoneal carcinoma
    • Abstract 306
    • Campos S, Penson R, Berlin S, Matulonis U, Horowitz N (2010) A phase II trial of sunitinib in recurrent and refractory ovarian, fallopian tube, and peritoneal carcinoma. Gynecol Oncol 116:S119-S120. Abstract 306
    • (2010) Gynecol Oncol , vol.116
    • Campos, S.1    Penson, R.2    Berlin, S.3    Matulonis, U.4    Horowitz, N.5
  • 82
    • 83255192931 scopus 로고    scopus 로고
    • Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a phase II randomized discontinuation trial (RDT)
    • Abstract 5008
    • Buckanovich RJ, Berger R, Sella A, Sikic BI, Shen X, Ramies DA, Smith DC, Vergote IB (2011) Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a phase II randomized discontinuation trial (RDT). J Clin Oncol 29: Abstract 5008
    • (2011) J Clin Oncol , vol.29
    • Buckanovich, R.J.1    Berger, R.2    Sella, A.3    Sikic, B.I.4    Shen, X.5    Ramies, D.A.6    Smith, D.C.7    Vergote, I.B.8
  • 83
    • 33745867638 scopus 로고    scopus 로고
    • Poly(ADP-ribose): Novel functions for an old molecule
    • 16829982 1:CAS:528:DC%2BD28Xms1Ohsb4%3D
    • Schreiber V, Dantzer F, Ame JC, de Murcia G (2006) Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 7:517-528
    • (2006) Nat Rev Mol Cell Biol , vol.7 , pp. 517-528
    • Schreiber, V.1    Dantzer, F.2    Ame, J.C.3    De Murcia, G.4
  • 84
    • 0344875495 scopus 로고    scopus 로고
    • Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination
    • 12930944 1:CAS:528:DC%2BD3sXmvVWrt78%3D
    • Schultz N, Lopez E, Saleh-Gohari N, Helleday T (2003) Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. Nucleic Acids Res 31:4959-4964
    • (2003) Nucleic Acids Res , vol.31 , pp. 4959-4964
    • Schultz, N.1    Lopez, E.2    Saleh-Gohari, N.3    Helleday, T.4
  • 85
    • 49249119415 scopus 로고    scopus 로고
    • A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair
    • 18591545 1:CAS:528:DC%2BD1cXhtVGjs7rL
    • Ashworth A (2008) A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26:3785-3790
    • (2008) J Clin Oncol , vol.26 , pp. 3785-3790
    • Ashworth, A.1
  • 86
    • 67650476607 scopus 로고    scopus 로고
    • Synthetic lethality-A new direction in cancer-drug development
    • 19553640 1:CAS:528:DC%2BD1MXosVKqurk%3D
    • Iglehart JD, Silver DP (2009) Synthetic lethality-a new direction in cancer-drug development. N Engl J Med 361:189-191
    • (2009) N Engl J Med , vol.361 , pp. 189-191
    • Iglehart, J.D.1    Silver, D.P.2
  • 87
    • 77956648238 scopus 로고    scopus 로고
    • Targeted trials in ovarian cancer
    • 20591473 1:CAS:528:DC%2BC3cXhtFClsbjO
    • Ledermann JA, Raja FA (2010) Targeted trials in ovarian cancer. Gynecol Oncol 119:151-156
    • (2010) Gynecol Oncol , vol.119 , pp. 151-156
    • Ledermann, J.A.1    Raja, F.A.2
  • 89
    • 30744445981 scopus 로고    scopus 로고
    • Hereditary breast and ovarian cancer: Review and future perspectives
    • Lux MP, Fasching PA, Beckmann MW (2006) Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med (Berl) 84:16-28
    • (2006) J Mol Med (Berl) , vol.84 , pp. 16-28
    • Lux, M.P.1    Fasching, P.A.2    Beckmann, M.W.3
  • 91
    • 0034307160 scopus 로고    scopus 로고
    • BRCA1 promoter region hypermethylation in ovarian carcinoma: A population-based study
    • 11034065 1:CAS:528:DC%2BD3cXns1ehsL4%3D
    • Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, Narod S, Karlan BY (2000) BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res 60:5329-5333
    • (2000) Cancer Res , vol.60 , pp. 5329-5333
    • Baldwin, R.L.1    Nemeth, E.2    Tran, H.3    Shvartsman, H.4    Cass, I.5    Narod, S.6    Karlan, B.Y.7
  • 92
    • 77955894453 scopus 로고    scopus 로고
    • Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer
    • 20547991 1:CAS:528:DC%2BC3cXhtFSksbzE
    • Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, Francoeur N, Levine DA, Cannistra SA (2010) Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 28:3555-3561
    • (2010) J Clin Oncol , vol.28 , pp. 3555-3561
    • Konstantinopoulos, P.A.1    Spentzos, D.2    Karlan, B.Y.3    Taniguchi, T.4    Fountzilas, E.5    Francoeur, N.6    Levine, D.A.7    Cannistra, S.A.8
  • 95
    • 79951549627 scopus 로고    scopus 로고
    • Preliminary experience with use of chemotherapy (CT) following treatment with olaparib, a poly(ADP-ribose) polymerase inhibitor (PARPi), in patients with BRCA1/2-deficient ovarian cancer (BDOC)
    • Abstract 5041
    • Ang J, Yap TA, Fong P, et al (2010) Preliminary experience with use of chemotherapy (CT) following treatment with olaparib, a poly(ADP-ribose) polymerase inhibitor (PARPi), in patients with BRCA1/2-deficient ovarian cancer (BDOC). J Clin Oncol 28: Abstract 5041
    • (2010) J Clin Oncol , vol.28
    • Ang, J.1    Yap, T.A.2    Fong, P.3
  • 97
  • 99
    • 80053578082 scopus 로고    scopus 로고
    • A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer
    • Abstract 5004
    • Penson RT, Whalen C, Lasonde B, et al (2011) A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer. J Clin Oncol 29: Abstract 5004
    • (2011) J Clin Oncol , vol.29
    • Penson, R.T.1    Whalen, C.2    Lasonde, B.3
  • 100
    • 80053600436 scopus 로고    scopus 로고
    • A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-resistant recurrent ovarian cancer
    • Abstract 5005
    • Birrer MJ, Konstantinopoulos P, Penson RT, Roche M, Ambrosio A, Stallings TE, Matulonis U, Bradley CR (2011) A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-resistant recurrent ovarian cancer. J Clin Oncol 29: Abstract 5005
    • (2011) J Clin Oncol , vol.29
    • Birrer, M.J.1    Konstantinopoulos, P.2    Penson, R.T.3    Roche, M.4    Ambrosio, A.5    Stallings, T.E.6    Matulonis, U.7    Bradley, C.R.8
  • 105
    • 57749113074 scopus 로고    scopus 로고
    • Drug resistance caused by reversion mutation
    • 19074863 1:CAS:528:DC%2BD1cXhsV2it7nL
    • Ashworth A (2008) Drug resistance caused by reversion mutation. Cancer Res 68:10021-10023
    • (2008) Cancer Res , vol.68 , pp. 10021-10023
    • Ashworth, A.1
  • 106
    • 78650674698 scopus 로고    scopus 로고
    • PI3K/AKT/mTOR inhibitors in ovarian cancer
    • 21062259 1:CAS:528:DC%2BC3cXhs1artr7O
    • Mazzoletti M, Broggini M (2010) PI3K/AKT/mTOR inhibitors in ovarian cancer. Curr Med Chem 17:4433-4447
    • (2010) Curr Med Chem , vol.17 , pp. 4433-4447
    • Mazzoletti, M.1    Broggini, M.2
  • 107
    • 32044466838 scopus 로고    scopus 로고
    • Exploiting the PI3K/AKT pathway for cancer drug discovery
    • 16341064 1:CAS:528:DC%2BD2MXht1yktbjI
    • Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4:988-1004
    • (2005) Nat Rev Drug Discov , vol.4 , pp. 988-1004
    • Hennessy, B.T.1    Smith, D.L.2    Ram, P.T.3    Lu, Y.4    Mills, G.B.5
  • 108
    • 65549167833 scopus 로고    scopus 로고
    • Targeting the mTOR signaling network for cancer therapy
    • 19332717 1:CAS:528:DC%2BD1MXlvFOgs7k%3D
    • Meric-Bernstam F, Gonzalez-Angulo AM (2009) Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 27:2278-2287
    • (2009) J Clin Oncol , vol.27 , pp. 2278-2287
    • Meric-Bernstam, F.1    Gonzalez-Angulo, A.M.2
  • 109
    • 4143111260 scopus 로고    scopus 로고
    • AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth
    • 15208673 1:CAS:528:DC%2BD2cXmtVCnsL4%3D
    • Altomare DA, Wang HQ, Skele KL, De RA, Klein-Szanto AJ, Godwin AK, Testa JR (2004) AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 23:5853-5857
    • (2004) Oncogene , vol.23 , pp. 5853-5857
    • Altomare, D.A.1    Wang, H.Q.2    Skele, K.L.3    De, R.A.4    Klein-Szanto, A.J.5    Godwin, A.K.6    Testa, J.R.7
  • 111
    • 84859378520 scopus 로고    scopus 로고
    • Minireview: Human ovarian cancer: Biology, current management, and paths to personalizing therapy
    • 22416079 1:CAS:528:DC%2BC38XlsVSnu7c%3D
    • Romero I, Bast RC Jr (2012) Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology 153:1593-1602
    • (2012) Endocrinology , vol.153 , pp. 1593-1602
    • Romero, I.1    Bast, Jr.R.C.2
  • 114
    • 79952665848 scopus 로고    scopus 로고
    • A phase i safety and pharmacokinetic (PK) study of PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors
    • Abstract 3078
    • Traynor AM, Kurzrock R, Bailey HH, Attia S, Scheffold C, van Leeuwen B, Wu B, Falchook GS, Moulder SL, Wheler J (2010) A phase I safety and pharmacokinetic (PK) study of PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors. J Clin Oncol 28: Abstract 3078
    • (2010) J Clin Oncol , vol.28
    • Traynor, A.M.1    Kurzrock, R.2    Bailey, H.H.3    Attia, S.4    Scheffold, C.5    Van Leeuwen, B.6    Wu, B.7    Falchook, G.S.8    Moulder, S.L.9    Wheler, J.10
  • 118
    • 34547130295 scopus 로고    scopus 로고
    • RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model
    • 17634556 1:CAS:528:DC%2BD2sXnvVChtr4%3D
    • Mabuchi S, Altomare DA, Cheung M, Zhang L, Poulikakos PI, Hensley HH, Schilder RJ, Ozols RF, Testa JR (2007) RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 13:4261-4270
    • (2007) Clin Cancer Res , vol.13 , pp. 4261-4270
    • Mabuchi, S.1    Altomare, D.A.2    Cheung, M.3    Zhang, L.4    Poulikakos, P.I.5    Hensley, H.H.6    Schilder, R.J.7    Ozols, R.F.8    Testa, J.R.9
  • 120
    • 77951938324 scopus 로고    scopus 로고
    • A phase i study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies
    • 20347480 1:CAS:528:DC%2BC3cXmtFajsbY%3D
    • Temkin SM, Yamada SD, Fleming GF (2010) A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies. Gynecol Oncol 117:473-476
    • (2010) Gynecol Oncol , vol.117 , pp. 473-476
    • Temkin, S.M.1    Yamada, S.D.2    Fleming, G.F.3
  • 121
    • 84861681565 scopus 로고    scopus 로고
    • A phase II trial of temsirolimus and bevacizumab in patients with endometrial, ovarian, hepatocellular carcinoma, carcinoid, or islet cell cancer: Ovarian cancer (OC) subset-A study of the Princess Margaret, Mayo, Southeast phase II, and California Cancer (CCCP) N01 Consortia NCI#8233
    • Abstract 5015
    • Morgan R, Oza AM, Qin R, Laumann KM, Mackay H, Strevel EL, Welch S, Sullivan D, Wenham RM, Chen HX, Doyle LA, Gandara DR, Erlichman C (2011) A phase II trial of temsirolimus and bevacizumab in patients with endometrial, ovarian, hepatocellular carcinoma, carcinoid, or islet cell cancer: Ovarian cancer (OC) subset-A study of the Princess Margaret, Mayo, Southeast phase II, and California Cancer (CCCP) N01 Consortia NCI#8233. J Clin Oncol 29: Abstract 5015
    • (2011) J Clin Oncol , vol.29
    • Morgan, R.1    Oza, A.M.2    Qin, R.3    Laumann, K.M.4    MacKay, H.5    Strevel, E.L.6    Welch, S.7    Sullivan, D.8    Wenham, R.M.9    Chen, H.X.10    Doyle, L.A.11    Gandara, D.R.12    Erlichman, C.13
  • 122
    • 80052588957 scopus 로고    scopus 로고
    • Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study
    • 21752435 1:CAS:528:DC%2BC3MXhtFGnsbjN
    • Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, Schilder RJ, Cai KQ, Godwin AK, Alpaugh RK (2011) Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol 123:19-26
    • (2011) Gynecol Oncol , vol.123 , pp. 19-26
    • Behbakht, K.1    Sill, M.W.2    Darcy, K.M.3    Rubin, S.C.4    Mannel, R.S.5    Waggoner, S.6    Schilder, R.J.7    Cai, K.Q.8    Godwin, A.K.9    Alpaugh, R.K.10
  • 125
    • 2542547908 scopus 로고    scopus 로고
    • Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation
    • 14617782 1:CAS:528:DC%2BD3sXovFCqtLw%3D
    • Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK (2003) Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2:1093-1103
    • (2003) Mol Cancer Ther , vol.2 , pp. 1093-1103
    • Kondapaka, S.B.1    Singh, S.S.2    Dasmahapatra, G.P.3    Sausville, E.A.4    Roy, K.K.5
  • 126
    • 79951725560 scopus 로고    scopus 로고
    • Induction of programmed cell death by inhibition of AKT with the alkylphosphocholine perifosine in in vitro models of platinum sensitive and resistant ovarian cancers
    • 20405296
    • Engel JB, Schonhals T, Hausler S, Krockenberger M, Schmidt M, Horn E, Koster F, Dietl J, Wischhusen J, Honig A (2010) Induction of programmed cell death by inhibition of AKT with the alkylphosphocholine perifosine in in vitro models of platinum sensitive and resistant ovarian cancers. Arch Gynecol Obstet 283:603-610
    • (2010) Arch Gynecol Obstet , vol.283 , pp. 603-610
    • Engel, J.B.1    Schonhals, T.2    Hausler, S.3    Krockenberger, M.4    Schmidt, M.5    Horn, E.6    Koster, F.7    Dietl, J.8    Wischhusen, J.9    Honig, A.10
  • 132
    • 69549083525 scopus 로고    scopus 로고
    • Promising molecular targets in ovarian cancer
    • 19553815
    • Blagden S, Gabra H (2009) Promising molecular targets in ovarian cancer. Curr Opin Oncol 21:412-419
    • (2009) Curr Opin Oncol , vol.21 , pp. 412-419
    • Blagden, S.1    Gabra, H.2
  • 133
    • 0032812095 scopus 로고    scopus 로고
    • Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model
    • 10473101 1:STN:280:DyaK1MvgtVSrsg%3D%3D
    • Wiener JR, Nakano K, Kruzelock RP, Bucana CD, Bast RC Jr, Gallick GE (1999) Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model. Clin Cancer Res 5:2164-2170
    • (1999) Clin Cancer Res , vol.5 , pp. 2164-2170
    • Wiener, J.R.1    Nakano, K.2    Kruzelock, R.P.3    Bucana, C.D.4    Bast, Jr.R.C.5    Gallick, G.E.6
  • 135
    • 14844333242 scopus 로고    scopus 로고
    • Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3
    • 15713893 1:CAS:528:DC%2BD2MXhtleku7s%3D
    • Chen T, Pengetnze Y, Taylor CC (2005) Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3. Mol Cancer Ther 4:217-224
    • (2005) Mol Cancer Ther , vol.4 , pp. 217-224
    • Chen, T.1    Pengetnze, Y.2    Taylor, C.C.3
  • 136
    • 0041422435 scopus 로고    scopus 로고
    • Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line
    • 12951060 1:CAS:528:DC%2BD3sXmvVKnu78%3D
    • Pengetnze Y, Steed M, Roby KF, Terranova PF, Taylor CC (2003) Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line. Biochem Biophys Res Commun 309:377-383
    • (2003) Biochem Biophys Res Commun , vol.309 , pp. 377-383
    • Pengetnze, Y.1    Steed, M.2    Roby, K.F.3    Terranova, P.F.4    Taylor, C.C.5
  • 139
    • 80053237246 scopus 로고    scopus 로고
    • A randomized phase II clinical trial of the Src inhibitor saracatinib (AZD0530) and carboplatin + paclitaxel (C + P) versus C + P in patients (pts) with advanced platinum-sensitive epithelial ovarian cancer (EOC)
    • Abstract 9720
    • Poole C, Lisyanskaya A, Rodenhuis S, Kristensen G, Pujade-Lauraine E, Cantarini M, Emeribe U, Stuart M, Ray-Coquard I (2010) A randomized phase II clinical trial of the Src inhibitor saracatinib (AZD0530) and carboplatin + paclitaxel (C + P) versus C + P in patients (pts) with advanced platinum-sensitive epithelial ovarian cancer (EOC). Ann Oncol 21:viii304. doi: Abstract9720
    • (2010) Ann Oncol , vol.21 , pp. 304
    • Poole, C.1    Lisyanskaya, A.2    Rodenhuis, S.3    Kristensen, G.4    Pujade-Lauraine, E.5    Cantarini, M.6    Emeribe, U.7    Stuart, M.8    Ray-Coquard, I.9
  • 140
    • 41949100690 scopus 로고    scopus 로고
    • Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer
    • 18291115 1:CAS:528:DC%2BD1cXkvFWlurk%3D
    • Lafky JM, Wilken JA, Baron AT, Maihle NJ (2008) Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta 1785:232-265
    • (2008) Biochim Biophys Acta , vol.1785 , pp. 232-265
    • Lafky, J.M.1    Wilken, J.A.2    Baron, A.T.3    Maihle, N.J.4
  • 141
    • 0034722889 scopus 로고    scopus 로고
    • The EGF receptor family as targets for cancer therapy
    • 11426640 1:CAS:528:DC%2BD3MXhsF2ku7k%3D
    • Mendelsohn J, Baselga J (2000) The EGF receptor family as targets for cancer therapy. Oncogene 19:6550-6565
    • (2000) Oncogene , vol.19 , pp. 6550-6565
    • Mendelsohn, J.1    Baselga, J.2
  • 144
    • 28944439741 scopus 로고    scopus 로고
    • Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: Results from a phase II multicenter study
    • 16174225 1:STN:280:DC%2BD2Mrgt1KksA%3D%3D
    • Gordon AN, Finkler N, Edwards RP, Garcia AA, Crozier M, Irwin DH, Barrett E (2005) Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer 15:785-792
    • (2005) Int J Gynecol Cancer , vol.15 , pp. 785-792
    • Gordon, A.N.1    Finkler, N.2    Edwards, R.P.3    Garcia, A.A.4    Crozier, M.5    Irwin, D.H.6    Barrett, E.7
  • 146
    • 74249089783 scopus 로고    scopus 로고
    • Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074)
    • 20109725 1:CAS:528:DC%2BC3cXntVSjtA%3D%3D
    • Pautier P, Joly F, Kerbrat P, Bougnoux P, Fumoleau P, Petit T, Rixe O, Ringeisen F, Carrasco AT, Lhomme C (2010) Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074). Gynecol Oncol 116:157-162
    • (2010) Gynecol Oncol , vol.116 , pp. 157-162
    • Pautier, P.1    Joly, F.2    Kerbrat, P.3    Bougnoux, P.4    Fumoleau, P.5    Petit, T.6    Rixe, O.7    Ringeisen, F.8    Carrasco, A.T.9    Lhomme, C.10
  • 147
    • 44349178606 scopus 로고    scopus 로고
    • A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
    • 18506181 1:CAS:528:DC%2BD1cXmtlCis78%3D
    • Vasey PA, Gore M, Wilson R, Rustin G, Gabra H, Guastalla JP, Lauraine EP, Paul J, Carty K, Kaye S (2008) A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. Br J Cancer 98:1774-1780
    • (2008) Br J Cancer , vol.98 , pp. 1774-1780
    • Vasey, P.A.1    Gore, M.2    Wilson, R.3    Rustin, G.4    Gabra, H.5    Guastalla, J.P.6    Lauraine, E.P.7    Paul, J.8    Carty, K.9    Kaye, S.10
  • 148
    • 0037440042 scopus 로고    scopus 로고
    • Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group
    • 12525520 1:CAS:528:DC%2BD2cXpsVWqs70%3D
    • Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR (2003) Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 21:283-290
    • (2003) J Clin Oncol , vol.21 , pp. 283-290
    • Bookman, M.A.1    Darcy, K.M.2    Clarke-Pearson, D.3    Boothby, R.A.4    Horowitz, I.R.5
  • 150
    • 80053254746 scopus 로고    scopus 로고
    • Combined topotecan and lapatinib in patients with early recurrent ovarian and peritoneal cancer after first line of platinum-based chemotherapy: A French FEDEGYN-FNCLCC Phase II trial
    • Abstract 5555
    • Joly F, Weber B, Pautier P, Fabbro M, Selle F, Krieger S, Leconte A, Bourgeois H, Henry-Amar M (2009) Combined topotecan and lapatinib in patients with early recurrent ovarian and peritoneal cancer after first line of platinum-based chemotherapy: a French FEDEGYN-FNCLCC Phase II trial. J Clin Oncol 27: Abstract 5555
    • (2009) J Clin Oncol , vol.27
    • Joly, F.1    Weber, B.2    Pautier, P.3    Fabbro, M.4    Selle, F.5    Krieger, S.6    Leconte, A.7    Bourgeois, H.8    Henry-Amar, M.9
  • 151
    • 60749092998 scopus 로고    scopus 로고
    • Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash
    • 19162309 1:CAS:528:DC%2BD1MXjsVKrsrk%3D
    • Schilder RJ, Pathak HB, Lokshin AE, Holloway RW, Alvarez RD, Aghajanian C, Min H, Devarajan K, Ross E, Drescher CW, Godwin AK (2009) Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol 113:21-27
    • (2009) Gynecol Oncol , vol.113 , pp. 21-27
    • Schilder, R.J.1    Pathak, H.B.2    Lokshin, A.E.3    Holloway, R.W.4    Alvarez, R.D.5    Aghajanian, C.6    Min, H.7    Devarajan, K.8    Ross, E.9    Drescher, C.W.10    Godwin, A.K.11
  • 152
    • 47249145102 scopus 로고    scopus 로고
    • A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer
    • 18554700 1:CAS:528:DC%2BD1cXoslWmsbs%3D
    • Konner J, Schilder RJ, DeRosa FA, Gerst SR, Tew WP, Sabbatini PJ, Hensley ML, Spriggs DR, Aghajanian CA (2008) A phase II study of cetuximab/paclitaxel/ carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer. Gynecol Oncol 110:140-145
    • (2008) Gynecol Oncol , vol.110 , pp. 140-145
    • Konner, J.1    Schilder, R.J.2    Derosa, F.A.3    Gerst, S.R.4    Tew, W.P.5    Sabbatini, P.J.6    Hensley, M.L.7    Spriggs, D.R.8    Aghajanian, C.A.9
  • 153
    • 39249085402 scopus 로고    scopus 로고
    • Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: A Gynecologic Oncology Group study
    • 18191993 1:CAS:528:DC%2BD1cXitlCjsbs%3D
    • Secord AA, Blessing JA, Armstrong DK, Rodgers WH, Miner Z, Barnes MN, Lewandowski G, Mannel RS (2008) Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol Oncol 108:493-499
    • (2008) Gynecol Oncol , vol.108 , pp. 493-499
    • Secord, A.A.1    Blessing, J.A.2    Armstrong, D.K.3    Rodgers, W.H.4    Miner, Z.5    Barnes, M.N.6    Lewandowski, G.7    Mannel, R.S.8
  • 155
    • 60749131575 scopus 로고    scopus 로고
    • A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab (P) versus carboplatin-based therapy alone in patients with relapsed, platinum sensitive ovarian cancer
    • Abstract 5520
    • Kaye SB, Poole CJ, Bidzinksi M, Gianni L, Gorbunova V, Novikova E, Strauss A, McNally VA, Ross G, Vergote I (2008) A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab (P) versus carboplatin-based therapy alone in patients with relapsed, platinum sensitive ovarian cancer. J Clin Oncol 26: Abstract 5520
    • (2008) J Clin Oncol , vol.26
    • Kaye, S.B.1    Poole, C.J.2    Bidzinksi, M.3    Gianni, L.4    Gorbunova, V.5    Novikova, E.6    Strauss, A.7    McNally, V.A.8    Ross, G.9    Vergote, I.10
  • 159
    • 74549205168 scopus 로고    scopus 로고
    • Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2
    • 20068097 1:CAS:528:DC%2BC3cXktF2qt7Y%3D
    • Annunziata CM, Walker AJ, Minasian L, Yu M, Kotz H, Wood BJ, Calvo K, Choyke P, Kimm D, Steinberg SM, Kohn EC (2010) Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. Clin Cancer Res 16:664-672
    • (2010) Clin Cancer Res , vol.16 , pp. 664-672
    • Annunziata, C.M.1    Walker, A.J.2    Minasian, L.3    Yu, M.4    Kotz, H.5    Wood, B.J.6    Calvo, K.7    Choyke, P.8    Kimm, D.9    Steinberg, S.M.10    Kohn, E.C.11
  • 163
    • 78649926327 scopus 로고    scopus 로고
    • Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: Final data from a multicenter phase II study
    • Abstract 5001
    • White AJ, Coleman RL, Armstrong DK, Glenn D, Bicher A, Richards DA, Schneeweiss A, Old LJ, Schweizer C, Weil S (2010) Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: final data from a multicenter phase II study. J Clin Oncol 28: Abstract 5001
    • (2010) J Clin Oncol , vol.28
    • White, A.J.1    Coleman, R.L.2    Armstrong, D.K.3    Glenn, D.4    Bicher, A.5    Richards, D.A.6    Schneeweiss, A.7    Old, L.J.8    Schweizer, C.9    Weil, S.10
  • 164
    • 80052966129 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of farletuzumab (MORAb-003) in combination with weekly paclitaxel in subjects with platinum-resistant or refractory relapsed ovarian cancer
    • Abstract TPS255
    • Elit L, Konner JA, Armstrong DK, Buck M, Dean A, Finkler NJ, Hulstine A, Schweizer C, Phillips M, Weil S (2010) A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of farletuzumab (MORAb-003) in combination with weekly paclitaxel in subjects with platinum-resistant or refractory relapsed ovarian cancer. J Clin Oncol 28: Abstract TPS255
    • (2010) J Clin Oncol , vol.28
    • Elit, L.1    Konner, J.A.2    Armstrong, D.K.3    Buck, M.4    Dean, A.5    Finkler, N.J.6    Hulstine, A.7    Schweizer, C.8    Phillips, M.9    Weil, S.10
  • 165
    • 79961137145 scopus 로고    scopus 로고
    • PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinumresistant ovarian cancer
    • Abstract 5045
    • Naumann RW et al (2011) PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinumresistant ovarian cancer. J Clin Oncol 29:343s, Abstract 5045
    • (2011) J Clin Oncol , vol.29
    • Naumann, R.W.1
  • 166
    • 0036111682 scopus 로고    scopus 로고
    • Insulin-like growth factors and cancer
    • 12067807 1:CAS:528:DC%2BD38XktlWhsb0%3D
    • Furstenberger G, Senn HJ (2002) Insulin-like growth factors and cancer. Lancet Oncol 3:298-302
    • (2002) Lancet Oncol , vol.3 , pp. 298-302
    • Furstenberger, G.1    Senn, H.J.2
  • 167
    • 0036721496 scopus 로고    scopus 로고
    • Functional insulin receptors on human epithelial ovarian carcinoma cells: Implications for IGF-II mitogenic signaling
    • 12193537 1:CAS:528:DC%2BD38XmsVSgt7g%3D
    • Kalli KR, Falowo OI, Bale LK, Zschunke MA, Roche PC, Conover CA (2002) Functional insulin receptors on human epithelial ovarian carcinoma cells: implications for IGF-II mitogenic signaling. Endocrinology 143:3259-3267
    • (2002) Endocrinology , vol.143 , pp. 3259-3267
    • Kalli, K.R.1    Falowo, O.I.2    Bale, L.K.3    Zschunke, M.A.4    Roche, P.C.5    Conover, C.A.6
  • 169
    • 79959838081 scopus 로고    scopus 로고
    • Integrated genomic analyses of ovarian carcinoma
    • Cancer Genome Atlas Research Network
    • Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474:609-615
    • (2011) Nature , vol.474 , pp. 609-615
  • 170
    • 78649237831 scopus 로고    scopus 로고
    • Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents
    • 20406171 1:CAS:528:DC%2BC3cXhtVOmu7%2FN
    • Leijen S, Beijnen JH, Schellens JH (2010) Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. Curr Clin Pharmacol 5:186-191
    • (2010) Curr Clin Pharmacol , vol.5 , pp. 186-191
    • Leijen, S.1    Beijnen, J.H.2    Schellens, J.H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.